UNSPSC 51162002: Albuterol/ipratropium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162002 Albuterol/ipratropium is a Commodity code that encompasses individual pharmaceutical products and related pharmacy services procured by state and local governments. However, the recent state and local opportunities tagged under this code show substantial mismatch with the nominal scope—the solicitations involve naloxone and drug deactivation systems, on-site pharmacy services delivery, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals distribution, none of which center on the specific albuterol/ipratropium combination indicated by the code number. State and local buyers under this code include county health departments and community health initiatives (Seminole County, Florida), county government employee health plans (Hall County, Georgia), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states and local jurisdictions (MMCAP, administered by Minnesota Department of Administration). The work being solicited ranges from procurement of discrete naloxone units for community health programs to comprehensive on-site pharmacy services operations, to establishment of wholesaler-based distribution agreements for generic pharmaceuticals and OTC products across multi-state networks.

Recent activity spans Florida, Georgia, Texas, and Minnesota-led multi-state purchasing. Representative opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023; Hall County, Georgia's RFQ/P #47-010 for on-site pharmacy services at its Family Health Center with a response deadline of June 4, 2026; Texas Health and Human Services Commission's Request for Information (RFI) No. HHS0017013 on direct-to-manufacturer prescription programs, posted April 3, 2026; and MMCAP's Request for Proposal for generic multi-source pharmaceuticals and OTC products with a due date of March 26, 2026 and contract effective date of July 1, 2026. The code shows activity across multiple jurisdiction types but exhibits poor alignment between the UNSPSC category name and the actual procurement scope—vendors pursuing this code should verify that opportunities tagged under 51162002 match their product or service line before responding.